OTHER (INCOME)/EXPENSE, NET

12 Months Ended

Dec. 31, 2022

Other Nonoperating Income (Expense) [Abstract]

Other (Income) / Expense, net

OTHER (INCOME)/EXPENSE, NET

	Year Ended December 31,
Dollars in Millions	2022		2021		2020
Interest expense	$	1,232	$	1,334	$	1,420
Royalty and licensing income (Note 4)	(1,283)		(1,067)		(883)
Royalty income - divestitures (Note 4)	(832)		(666)		(644)
Equity investment losses/(income), net (Note 9)	801		(745)		(1,228)
Integration expenses (Note 6)	440		564		717
Loss on debt redemption (Note 9)	266		281		—
Divestiture gains (Note 4)	(211)		(9)		(55)
Litigation and other settlements	178		82		(194)
Investment income	(171)		(39)		(121)
Provision for restructuring (Note 6)	75		169		530
Contingent consideration	(9)		(542)		(1,757)
Other	90		(82)		(99)
Other (income)/expense, net	$	576	$	(720)	$	(2,314)

Contingent Consideration

Contingent consideration in 2021 and 2020 primarily included fair value adjustments resulting from the change in the traded price of contingent value rights issued with the Celgene acquisition. The contractual obligation to pay the contingent value rights terminated in January 2021 because the FDA did not approve liso-cel (JCAR017) by December 31, 2020.